RDHLNasdaqPharmaceutical Preparations

RedHill Biopharma Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026

$0.50+0.02 (+4.39%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

RedHill Biopharma Ltd. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Cash & Equivalents	3.97	4.62	5.57	20	29	29	29	29	16	54	22	5.89
Cash & Short-Term Investments	3.97	4.62	5.57	20	29	29	29	29	16	54	22	5.89
Receivables	0.08	2.54	2.59	35	32	29	1.22	0.96	1.53	0.10	–	–
Inventory	–	3.65	4.39	11	15	6.53	1.88	0.77	0.65	–	–	–
Total Current Assets	6.53	12	16	86	89	70	53	57	52	68	–	–
Property, Plant & Equipment	0.05	0.14	0.19	0.50	0.57	0.51	0.23	0.16	0.23	0.17	–	–
Operating Lease Right-of-Use Assets	1.06	0.30	0.99	6.69	3.65	5.19	3.58	1.67	–	–	–	–
Intangible Assets	5.29	5.55	5.58	66	72	88	17	5.32	5.29	6.10	–	–
Total Assets	25	18	23	159	181	180	74	62	57	74	–	–
Accounts Payable	0.73	1.17	3.28	4.23	12	12	4.18	3.32	4.81	0.06	–	–
Short-Term Debt	–	–	–	115	–	–	–	–	–	–	–	–
Current Debt	–	–	–	115	–	–	–	–	–	–	–	–
Current Portion of Leases	0.17	0.35	0.72	1.03	1.62	1.71	0.83	0.90	–	–	–	–
Other Current Liabilities	2.08	0.50	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	19	22	20	197	81	73	11	10	12	5.36	–	–
Long-Term Debt	–	–	–	–	84	81	–	–	–	–	–	–
Long-Term Leases	0.90	0.00	0.46	6.44	2.57	3.81	2.98	0.77	–	–	–	–
Operating Lease Liabilities	1.07	0.36	1.17	7.48	4.19	5.52	3.82	1.67	–	–	–	–
Total Liabilities	21	23	21	207	172	166	14	11	12	12	–	–
Total Debt	–	–	–	115	84	81	–	–	–	–	–	–
Common Stock	148	35	21	2.84	1.50	1.05	0.96	0.77	0.58	0.44	–	–
Additional Paid-In Capital	–	–	388	383	375	293	267	220	177	151	–	–
Retained Earnings	-414	-415	-408	-434	-368	-280	-208	-169	-133	-90	–	–
Total Equity	4.27	-4.68	2.07	-48	8.88	14	60	51	45	63	60	25
Total Liabilities & Equity	25	18	23	159	181	180	74	62	57	74	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -2776.9%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 0.34
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 20.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –